首页 > 最新文献

Archivos De Bronconeumologia最新文献

英文 中文
Right Cardiac Bronchus: An Uncommon Incidental Finding 右心支气管:一个不常见的偶然发现。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.012
Álvaro Fuentes-Martín , María Rosa López Pedreira , Ángel Cilleruelo Ramos
{"title":"Right Cardiac Bronchus: An Uncommon Incidental Finding","authors":"Álvaro Fuentes-Martín , María Rosa López Pedreira , Ángel Cilleruelo Ramos","doi":"10.1016/j.arbres.2025.06.012","DOIUrl":"10.1016/j.arbres.2025.06.012","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 803-804"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Biomarkers Galectin-9 and TIM-3 Predict Melanoma and Lung Cancer Mortality in Obstructive Sleep Apnoea 免疫检查点生物标志物半凝集素-9和TIM-3预测阻塞性睡眠呼吸暂停患者黑色素瘤和肺癌死亡率。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.03.018
Elena Díaz-García , Enrique Alfaro , Paula Pérez-Moreno , Cristina López-Fernández , Aldara García-Sánchez , Miguel Ángel Martínez-García , Eva Mañas , Irene Cano-Pumarega , Raquel Casitas , Francisco Campos-Rodríguez , Manuel Sánchez-de-la-Torre , Eduardo Nagore , Antonio Martorell-Calatayud , Luis Hernández Blasco , Esther Pastor , Jorge Abad-Capa , Josep María Montserrat , Valentín Cabriada-Nuño , Jaime Corral-Peñafiel , Eva Arias , Carolina Cubillos-Zapata

Objectives

Obstructive sleep apnoea (OSA) has been associated with increased cancer risk and mortality, yet specific biomarkers for patient stratification remain lacking. This study explores the role of immune checkpoint biomarkers, soluble Galectin-9 (sGalectin-9) and TIM-3 (sTIM-3), in identifying OSA patients at higher risk of cancer-related mortality.

Methods

We conducted a multicohort, prospective observational study including 684 patients, with and without cancer, who underwent sleep studies. Plasma levels of sGalectin-9 and sTIM-3 were assessed using bead-based multiplexed assays. In vitro and ex vivo models were employed to investigate the pathogenic mechanisms underlying biomarker upregulation and their immunological impact.

Results

In severe OSA patients with melanoma or lung cancer, sGalectin-9 and sTIM-3 were associated with tumour aggressiveness and with an increased mortality risk. In the three study cohorts, biomarker levels were higher in severe OSA patients than in the other groups. In non-cancer OSA patients’ monocyte intracellular Galectin-9 and T-lymphocyte membrane-bound TIM-3 were upregulated. Experimental data revealed that intermittent hypoxia drove the expression of these biomarkers, which were positively associated with inflammatory mediators and inversely related to T-cell proliferation and infiltration. These findings underscore a mechanistic link between hypoxemia and immune suppression.

Interpretation

sGalectin-9 and sTIM-3 are promising prognostic biomarkers for medium- to long-term survival in OSA patients with melanoma or lung cancer. Their upregulation highlights a potential pathophysiological pathway connecting OSA-induced hypoxemia to cancer aggressiveness through immune modulation. Further validation could inform risk stratification and personalised therapeutic strategies.
目的:阻塞性睡眠呼吸暂停(OSA)与癌症风险和死亡率增加有关,但仍缺乏用于患者分层的特异性生物标志物。本研究探讨了免疫检查点生物标志物可溶性半乳糖凝集素-9 (sGalectin-9)和TIM-3 (sTIM-3)在识别OSA患者癌症相关死亡率较高风险中的作用。方法:我们进行了一项多队列、前瞻性观察研究,包括684例患者,有或无癌症,他们接受了睡眠研究。血浆中半乳糖凝集素-9和sTIM-3的水平采用基于头部的多重检测方法进行评估。采用体外和离体模型研究生物标志物上调的致病机制及其免疫学影响。结果:在伴有黑色素瘤或肺癌的严重OSA患者中,sGalectin-9和sTIM-3与肿瘤侵袭性和死亡风险增加相关。在三个研究队列中,重度OSA患者的生物标志物水平高于其他组。非癌性OSA患者单核细胞内半乳糖凝集素-9和t淋巴细胞膜结合TIM-3上调。实验数据显示,间歇性缺氧驱动这些生物标志物的表达,这些生物标志物与炎症介质呈正相关,与t细胞增殖和浸润呈负相关。这些发现强调了低氧血症和免疫抑制之间的机制联系。结论:半乳糖凝集素-9和sTIM-3是OSA合并黑色素瘤或肺癌患者中长期生存的预后生物标志物。它们的上调强调了通过免疫调节将osa诱导的低氧血症与癌症侵袭性联系起来的潜在病理生理途径。进一步的验证可以为风险分层和个性化治疗策略提供信息。
{"title":"Immune Checkpoint Biomarkers Galectin-9 and TIM-3 Predict Melanoma and Lung Cancer Mortality in Obstructive Sleep Apnoea","authors":"Elena Díaz-García ,&nbsp;Enrique Alfaro ,&nbsp;Paula Pérez-Moreno ,&nbsp;Cristina López-Fernández ,&nbsp;Aldara García-Sánchez ,&nbsp;Miguel Ángel Martínez-García ,&nbsp;Eva Mañas ,&nbsp;Irene Cano-Pumarega ,&nbsp;Raquel Casitas ,&nbsp;Francisco Campos-Rodríguez ,&nbsp;Manuel Sánchez-de-la-Torre ,&nbsp;Eduardo Nagore ,&nbsp;Antonio Martorell-Calatayud ,&nbsp;Luis Hernández Blasco ,&nbsp;Esther Pastor ,&nbsp;Jorge Abad-Capa ,&nbsp;Josep María Montserrat ,&nbsp;Valentín Cabriada-Nuño ,&nbsp;Jaime Corral-Peñafiel ,&nbsp;Eva Arias ,&nbsp;Carolina Cubillos-Zapata","doi":"10.1016/j.arbres.2025.03.018","DOIUrl":"10.1016/j.arbres.2025.03.018","url":null,"abstract":"<div><h3>Objectives</h3><div>Obstructive sleep apnoea (OSA) has been associated with increased cancer risk and mortality, yet specific biomarkers for patient stratification remain lacking. This study explores the role of immune checkpoint biomarkers, soluble Galectin-9 (sGalectin-9) and TIM-3 (sTIM-3), in identifying OSA patients at higher risk of cancer-related mortality.</div></div><div><h3>Methods</h3><div>We conducted a multicohort, prospective observational study including 684 patients, with and without cancer, who underwent sleep studies. Plasma levels of sGalectin-9 and sTIM-3 were assessed using bead-based multiplexed assays. In vitro and ex vivo models were employed to investigate the pathogenic mechanisms underlying biomarker upregulation and their immunological impact.</div></div><div><h3>Results</h3><div>In severe OSA patients with melanoma or lung cancer, sGalectin-9 and sTIM-3 were associated with tumour aggressiveness and with an increased mortality risk. In the three study cohorts, biomarker levels were higher in severe OSA patients than in the other groups. In non-cancer OSA patients’ monocyte intracellular Galectin-9 and T-lymphocyte membrane-bound TIM-3 were upregulated. Experimental data revealed that intermittent hypoxia drove the expression of these biomarkers, which were positively associated with inflammatory mediators and inversely related to T-cell proliferation and infiltration. These findings underscore a mechanistic link between hypoxemia and immune suppression.</div></div><div><h3>Interpretation</h3><div>sGalectin-9 and sTIM-3 are promising prognostic biomarkers for medium- to long-term survival in OSA patients with melanoma or lung cancer. Their upregulation highlights a potential pathophysiological pathway connecting OSA-induced hypoxemia to cancer aggressiveness through immune modulation. Further validation could inform risk stratification and personalised therapeutic strategies.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 735-748"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 46-Year-Old Female With a Left Bronchial Neoplasm Swaying With Respiration 46岁女性左支气管肿瘤伴呼吸摆动。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.013
Qinglin Zhong , Binglin Lai
{"title":"A 46-Year-Old Female With a Left Bronchial Neoplasm Swaying With Respiration","authors":"Qinglin Zhong ,&nbsp;Binglin Lai","doi":"10.1016/j.arbres.2025.06.013","DOIUrl":"10.1016/j.arbres.2025.06.013","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 805-806"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COPD and Frailty: Results of a Study Using the Delphi Method COPD与衰弱:一项使用德尔菲法的研究结果。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.008
Roberto Bernabéu-Mora , Pilar Cubo Romano , Iñaki Martín Lesende , Elsa Naval Sendra , Juan José Soler-Cataluña , Francisco José Tarazona-Santabalbina
{"title":"COPD and Frailty: Results of a Study Using the Delphi Method","authors":"Roberto Bernabéu-Mora ,&nbsp;Pilar Cubo Romano ,&nbsp;Iñaki Martín Lesende ,&nbsp;Elsa Naval Sendra ,&nbsp;Juan José Soler-Cataluña ,&nbsp;Francisco José Tarazona-Santabalbina","doi":"10.1016/j.arbres.2025.06.008","DOIUrl":"10.1016/j.arbres.2025.06.008","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 783-786"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Failure, Late Failure, and Sustained Response to Biologics in Severe Asthma: A Long-term, Real-world, Multicentre study 重度哮喘早期衰竭、晚期衰竭和对生物制剂的持续反应:一项长期、真实、多中心的研究。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.04.003
D. Dacal Rivas , E. Martinez-Moragón , V. Plaza , C. Cisneros Serrano , C. Benchimol , H. Izaguirre Flores , S. Sánchez-Cuéllar , M.D. Martínez-Pitarch , C. Fernández Aracil , A. Trisán Alonso , J.C. Serrano Rebollo , Z. Vásquez Gambasica , R.M. Díaz Campos , P. Trujillo Mulato , I. Escribano Gimeno , D. Laorden , E. Arismendi , N. Marina Malanda , A. De Diego Damia , M. Ferrer Galvan , L.A. Pérez de Llano

Objectives

Only one-third of patients with severe asthma (SA) achieve a complete response to biologics. This study aims to characterize two types of failure: early (EF), occurring ≤12 months after biologic initiation, and late (LF), occurring at any time during follow-up after response has been achieved at 12 months.

Methods

This is a multicentre retrospective study of adults treated with the same biologic for ≥24 months. Response was defined as no severe exacerbations in the preceding 12 months, asthma control test ≥20, and no need for maintenance oral corticosteroids. Failure (EF or LF) was defined as non-achievement of any of these objectives.

Results

Two hundred and seventy-two patients were analysed with a mean follow-up of 46.1 ± 19.4 months. At 12 months, 97/272 were classified as PF, but 40% of them recovered response on subsequent visits (by changing inhaled therapy in 74%). Among the 175 responders at 12 months, 124 (70.8%) maintained response throughout the study period, while 51 (29.1%) experienced SF; those patients had lower FEV1 values after 12 months of biological therapy. SF reverted in 36% of cases, with inhaled therapy changes in 41.6%. FEV1 decreased by ≥100 mL in 12 of 16 cases who did not recover response after SF.

Conclusion

Most patients who achieve response at 12 months maintain it over time, but 29% of them suffer LF. Optimization of inhaled therapy can aid response recovery from EF or LF. Maximizing pulmonary function helps to prevent loss of response.
目的:只有三分之一的严重哮喘(SA)患者对生物制剂有完全反应。本研究旨在描述两种类型的失败:早期(EF),发生在生物启动后≤12个月,晚期(LF),发生在12个月后达到反应后的随访期间的任何时间。方法:这是一项多中心回顾性研究,接受相同生物制剂治疗≥24个月的成年人。缓解的定义为在过去12个月内无严重恶化,哮喘控制试验≥20,不需要维持口服皮质类固醇。失败(EF或LF)被定义为没有实现这些目标中的任何一个。结果:分析了272例患者,平均随访时间为46.1±19.4个月。12个月时,272名患者中有97人被归类为PF,但其中40%的患者在随后的随访中恢复了缓解(74%的患者通过改变吸入治疗)。在175例12个月应答者中,124例(70.8%)在整个研究期间保持应答,51例(29.1%)发生SF;这些患者经过12个月的生物治疗后FEV1值降低。36%的患者SF恢复,41.6%的患者吸入治疗发生改变。SF后未恢复反应的16例患者中有12例FEV1下降≥100mL。结论:大多数在12个月时达到缓解的患者可以长期维持缓解,但29%的患者出现LF。优化吸入治疗有助于EF或LF的反应恢复。最大限度地发挥肺功能有助于防止反应丧失。
{"title":"Early Failure, Late Failure, and Sustained Response to Biologics in Severe Asthma: A Long-term, Real-world, Multicentre study","authors":"D. Dacal Rivas ,&nbsp;E. Martinez-Moragón ,&nbsp;V. Plaza ,&nbsp;C. Cisneros Serrano ,&nbsp;C. Benchimol ,&nbsp;H. Izaguirre Flores ,&nbsp;S. Sánchez-Cuéllar ,&nbsp;M.D. Martínez-Pitarch ,&nbsp;C. Fernández Aracil ,&nbsp;A. Trisán Alonso ,&nbsp;J.C. Serrano Rebollo ,&nbsp;Z. Vásquez Gambasica ,&nbsp;R.M. Díaz Campos ,&nbsp;P. Trujillo Mulato ,&nbsp;I. Escribano Gimeno ,&nbsp;D. Laorden ,&nbsp;E. Arismendi ,&nbsp;N. Marina Malanda ,&nbsp;A. De Diego Damia ,&nbsp;M. Ferrer Galvan ,&nbsp;L.A. Pérez de Llano","doi":"10.1016/j.arbres.2025.04.003","DOIUrl":"10.1016/j.arbres.2025.04.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Only one-third of patients with severe asthma (SA) achieve a complete response to biologics. This study aims to characterize two types of failure: early (EF), occurring ≤12 months after biologic initiation, and late (LF), occurring at any time during follow-up after response has been achieved at 12 months.</div></div><div><h3>Methods</h3><div>This is a multicentre retrospective study of adults treated with the same biologic for ≥24 months. Response was defined as no severe exacerbations in the preceding 12 months, asthma control test ≥20, and no need for maintenance oral corticosteroids. Failure (EF or LF) was defined as non-achievement of any of these objectives.</div></div><div><h3>Results</h3><div>Two hundred and seventy-two patients were analysed with a mean follow-up of 46.1<!--> <!-->±<!--> <!-->19.4 months. At 12 months, 97/272 were classified as PF, but 40% of them recovered response on subsequent visits (by changing inhaled therapy in 74%). Among the 175 responders at 12 months, 124 (70.8%) maintained response throughout the study period, while 51 (29.1%) experienced SF; those patients had lower FEV1 values after 12 months of biological therapy. SF reverted in 36% of cases, with inhaled therapy changes in 41.6%. FEV1 decreased by ≥100<!--> <!-->mL in 12 of 16 cases who did not recover response after SF.</div></div><div><h3>Conclusion</h3><div>Most patients who achieve response at 12 months maintain it over time, but 29% of them suffer LF. Optimization of inhaled therapy can aid response recovery from EF or LF. Maximizing pulmonary function helps to prevent loss of response.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 749-756"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Traumatic Pneumatoceles Mimicking Pulmonary Tuberculosis 外伤性肺泡模拟肺结核。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.006
Chee Kiang Phua , Ming Ren Toh , Chee Kiang Tay
{"title":"Traumatic Pneumatoceles Mimicking Pulmonary Tuberculosis","authors":"Chee Kiang Phua ,&nbsp;Ming Ren Toh ,&nbsp;Chee Kiang Tay","doi":"10.1016/j.arbres.2025.06.006","DOIUrl":"10.1016/j.arbres.2025.06.006","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 801-802"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bordetella bronchiseptica Pneumonia in an Immunocompetent Young Man 一个免疫能力强的年轻人的嗜支杆菌肺炎。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.07.015
Atif Saleem Siddiqui
{"title":"Bordetella bronchiseptica Pneumonia in an Immunocompetent Young Man","authors":"Atif Saleem Siddiqui","doi":"10.1016/j.arbres.2025.07.015","DOIUrl":"10.1016/j.arbres.2025.07.015","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 799-800"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood Pulmonary Virus Infection and Future Bronchiectasis 儿童肺部病毒感染与未来支气管扩张。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.05.019
Paul T. King
{"title":"Childhood Pulmonary Virus Infection and Future Bronchiectasis","authors":"Paul T. King","doi":"10.1016/j.arbres.2025.05.019","DOIUrl":"10.1016/j.arbres.2025.05.019","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 730-731"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Future of Sleep Apnea Research: From Foundational Discoveries to Personalized Medicine 睡眠呼吸暂停研究的未来:从基础发现到个性化医疗。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.011
Monica Levy Andersen , Sergio Brasil Tufik , Sergio Tufik
{"title":"The Future of Sleep Apnea Research: From Foundational Discoveries to Personalized Medicine","authors":"Monica Levy Andersen ,&nbsp;Sergio Brasil Tufik ,&nbsp;Sergio Tufik","doi":"10.1016/j.arbres.2025.06.011","DOIUrl":"10.1016/j.arbres.2025.06.011","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 732-734"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort 在MEGA队列中使用三种不同分类的哮喘生物标志物在两年期间的稳定性
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2025-12-01 DOI: 10.1016/j.arbres.2025.06.016
Diana Betancor , Manuel Jorge Rial , José María Olaguibel , Victoria Del Pozo , María José Alvarez Puebla , Ebymar Arismendi , Blanca Barroso , Irina Bobolea , Blanca Cárdaba , Jose Antonio Cañas , Javier Domínguez-Ortega , Astrid Crespo-Leshman , María Jesús Cruz , Alberto Garcia de la Fuente , Francisco-Javier González-Barcala , Jose Antonio Luna-Porta , Carlos Martínez-Rivera , Joaquim Mullol , Xavier Muñoz , Vicente Plaza , Joaquin Sastre
{"title":"Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort","authors":"Diana Betancor ,&nbsp;Manuel Jorge Rial ,&nbsp;José María Olaguibel ,&nbsp;Victoria Del Pozo ,&nbsp;María José Alvarez Puebla ,&nbsp;Ebymar Arismendi ,&nbsp;Blanca Barroso ,&nbsp;Irina Bobolea ,&nbsp;Blanca Cárdaba ,&nbsp;Jose Antonio Cañas ,&nbsp;Javier Domínguez-Ortega ,&nbsp;Astrid Crespo-Leshman ,&nbsp;María Jesús Cruz ,&nbsp;Alberto Garcia de la Fuente ,&nbsp;Francisco-Javier González-Barcala ,&nbsp;Jose Antonio Luna-Porta ,&nbsp;Carlos Martínez-Rivera ,&nbsp;Joaquim Mullol ,&nbsp;Xavier Muñoz ,&nbsp;Vicente Plaza ,&nbsp;Joaquin Sastre","doi":"10.1016/j.arbres.2025.06.016","DOIUrl":"10.1016/j.arbres.2025.06.016","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 12","pages":"Pages 794-796"},"PeriodicalIF":9.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archivos De Bronconeumologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1